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Aim To analyze the serum nicotinamide phosphoribosyl-
transferase (Nampt) level and its prognostic value in blad-
der cancer (BC).
Methods The study included 131 patients with transition-
al cell BC and 109 healthy controls from the West China 
Hospital of Sichuan University in the period between 2007 
and 2013. Nampt concentration in serum was measured 
by commercial ELISA kits for human Nampt.
Results The serum Nampt protein level in patients with BC 
(mean ± standard deviation, 16.02 ± 7.95 ng/mL) was sig-
nificantly higher than in the control group (6.46 ± 2.08 ng/
mL) (P < 0.001). Serum Nampt level was an independent 
prognostic marker of non-muscle-invasive BC, with a high-
er serum Nampt level (>14.74 ng/mL) indicating shorter 
recurrence-free survival rate (hazard ratio = 2.85, 95% con-
fidence interval, 1.01-8.06; P = 0.048).
Conclusion Our results suggest that serum Nampt level 
may serve as a biomarker of BC and an independent prog-
nostic marker of non-muscle-invasive BC.
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Bladder cancer (BC) is the ninth most common cancer di-
agnosis worldwide (1) and the most expensive cancer to 
treat (2). Among men it is the fourth most common can-
cer, with incidence four times higher than in women (3). 
In China, BC caused 17 365 deaths in 2005, with a steady 
increase in mortality between 1991 and 2005 (4). Of newly 
diagnosed BC cases, 70%-80% will present with non-mus-
cle-invasive disease, 50%-70% will recur despite endoscop-
ic and intravesical treatments, and 10%-30% will progress 
to muscle-invasive disease (5,6). Most recurrences occur 
within 5 years (7). Therefore, to develop improved, more 
effective prevention and treatments there is a need to find 
new biomarkers of tumorigenesis and prognosis of BC.
Nicotinamide phosphoribosyltransferase (Nampt) is a rate-
limiting enzyme in the mammalian NAD+ biosynthesis of 
a salvage pathway (8). Previous studies have shown that 
it is significantly increased in primary colorectal cancer 
(9-11), lung cancer (12), breast cancer (13), prostate cancer 
(14) and gastric cancer (15). Thus, Nampt may be a good 
biomarker of malignant potential and stage progression 
(12,16). Our previous study revealed that genetic variants 
in NAMPT may predict BC risk and prognosis (17). In the 
present study, we analyzed the serum Nampt level and its 
prognostic value in BC.
MateriaLS and MethodS
Study subjects
The study enrolled 131 patients with transitional cell BC 
(mean ± standard deviation [SD], 63.49 ± 12.96 years) and 
109 healthy controls (63.12 ± 10.28 years) (17). All partic-
ipants were recruited between 2007 and 2013 from the 
West China Hospital of Sichuan University. The diagnosis 
of BC was confirmed by histological tissue examination 
from biopsy or resected specimens. Seventy-two patients 
had muscle-invasive and 59 had non-muscle-invasive BC 
(Table 1). The control group consisted of 109 healthy in-
dividuals who underwent a routine health survey in the 
same hospital. We excluded those patients who had pre-
vious cancer, received radiotherapy or chemotherapy, had 
metastasized cancer from other or unknown origin, or had 
any other serious disease. Control subjects were geneti-
cally unrelated to the patients and to each other. All par-
ticipants were Han Chinese living in Sichuan province of 
the southwest China. The study was approved by the hos-
pital ethics committee and all participants gave a written 
informed consent.
investigation of plasma protein expression levels of 
nampt
Serum was obtained after centrifuging blood samples at 
1600 rpm for 10 min at 4°Cand stored at -80°C until analy-
sis. Nampt concentration in serum was measured by com-
mercial ELISA kits for human Nampt (USCNK, Wuhan, Chi-
na). The antibodies used in ELISA are specific for human 
Nampt. Analytical limit of detection of Nampt was 6.3 pg/
mL. The results are expressed in ng/mL.
rs61330082 genotyping
rs61330082, a single-nucleotide polymorphism (SNP) in the 
promoter region of NAMPT gene, was genotyped by poly-
merase chain reaction (PCR)-restriction fragment length 
polymorphism (RFLP) method (17).
Statistical analysis
Data were analyzed using SPSS for Windows software 
package, version 16.0 (SPSS Inc., Chicago, IL, USA). The dif-
ference in Nampt expression levels between BC patients 
and control group was tested by t test. The differences be-
tween serum Nampt level and genotypes of rs61330082 
were tested by one-way ANOVA analysis. Odds ratio (OR) 
taBLe 1. Clinicopathologic characteristics of 131 bladder 
cancer patients
Characteristics number of patients (%)
Sex
Male 107 (81.7)
Female  24 (18.3)
age
≤64  57 (43.5)
>64  74 (56.5)
Smoking
Smoking index >400  41 (31.3)
Smoking index ≤400  36 (27.5)
No  54 (41.2)
Grade
Low  60 (45.8)
High  71 (54.2)
invasiveness
Muscle-invasive  72 (55.0)
Non-muscle-invasive  59 (45.0)
relapse
Yes  90 (68.7)
No  41 (31.3)
Metastasis
Yes  20 (15.3)
No 111 (84.7)
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and 95% confidence intervals (CI) were used to assess the 
effects of serum Nampt protein level on the clinicopatho-
logical factors.
Recurrence-free survival (RFS) and overall survival (OS) 
were estimated using the Kaplan-Meier method, and the 
association of Nampt expression with RFS and OS was ex-
amined by a log-rank test. OS was the time from the day of 
diagnosis to the day of death or the last follow-up. RFS was 
the time from the day of diagnosis to the day of recurrence 
or death or the last follow-up. Prognostic factors were de-




The serum Nampt protein level in patients with BC (mean 
± SD, 16.02 ± 7.95 ng/mL) was significantly higher than 
in the control group (P < 0.001) (6.46 ± 2.08) (Figure 1). 
The median serum Nampt protein level was 14.74 ng/mL 
(range 3.44-50.15). The below median and above median 
levels were respectively found in 66 (50.4%) and 65 (49.6%) 
patients.
Of 131 BC patients genotyped for rs61330082, 39 were CC 
homozygous, 60 CT heterozygous, and 32 TT homozy-
gous. All observed genotype frequencies were in agree-
ment with the Hardy-Weinberg equilibrium expectations. 
One-way ANOVA analysis revealed no significant differ-
ences in serum Nampt level between the three genotypes 
(Figure 2).
relationship between serum nampt protein level and 
clinical pathological features of patients with BC
No significant correlation in BC patients was observed be-
tween serum Nampt protein level and clinical pathological 
features, including age, sex, smoking status, tumor grade, 
invasiveness, metastasis, and recurrence (Table 2).
Prognostic value of serum nampt level
Cox multivariable regression analysis showed that serum 
Nampt level was an independent prognostic marker of 
FiGure 1. Comparison of nicotinamide phosphoribosyltrans-
ferase (nampt) expression level between bladder cancer (BC) 
patients and controls.
FiGure 2. Comparison of nicotinamide phosphoribosyl-
transferase (nampt) expression level among three rs2505568 
genotypes.
FiGure 3. Kaplan-Meier recurrence-free survival curves for 
non-muscle-invasive bladder cancer patients based on serum 
nicotinamide phosphoribosyltransferase (nampt) level.
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non-muscle-invasive BC, with higher level (>14.74 ng/mL) 
indicating shorter recurrence-free survival rate (hazard ra-
tio = 2.85, 95% confidence interval = 1.01-8.06, P = 0.048) 
(Table 3). However, there was no significant association of 
serum Nampt level with RFS or OS in total BC patients and 
muscle-invasive BC patients (Figure 3).
taBLe 2. the relationship between serum nicotinamide phosphoribosyltransferase (nampt) and clinical pathological features of 
patients with bladder cancer
Serum nampt odds ratio
Pathological features n (%) ≤14.74 ng/mL >14.74 ng/mL (95%confidence interval) P (χ2 test)
age
≤64  57 (43.5) 24 33 1 (referent)
>64  74 (56.5) 42 32 0.554 (0.276-1.114) 0.096
Sex
Male 107 (81.7) 52 55 1 (referent)
Female  24 (18.3) 14 10 0.675 (0.276-1.654) 0.389
Smoking
No  54 (41.2) 27 27 1 (referent)
Smoking index ≤400  36 (27.5) 19 17 0.895 (0.385-2.081) 0.796
Smoking index >400  41 (31.3) 20 21 1.050 (0.466-2.365) 0.906
Grade
Low  60 (45.8) 28 32 1 (referent)
High  71 (54.2) 38 33 0.760 (0.382-1.513) 0.434
invasiveness
Muscle-invasive  72 (55.0) 37 35 1 (referent)
Non-muscle-invasive  59 (45.0) 29 30 0.094 (0.549-2.177) 0.799
relapse
No  90 (68.7) 48 42 1 (referent)
Yes  41 (31.3) 18 23 1.460 (0.695-3.070) 0.317
Metastases
No 111 (84.7) 55 56 1 (referent)
Yes  20 (15.3) 11  9 0.804 (0.309-2.091) 0.654
taBLe 3. association between nicotinamide phosphoribosyltransferase (nampt) level and patient’s survival
Multivariate survival analysis univariate survival analysis
























66 1 1 1 1
>14.74 
ng/mL





37 1 1 1 1
>14.74 
ng/mL






29 1 1 1 1
>14.74 
ng/mL
30 2.85 1.01-8.06 0.048 3.02 0.39-23.37 0.291 2.02 0.85-4.79 0.110 1.46 0.24-8.73 0.679
*adjusted for age, sex, smoking status, tumor stage, and tumor grade.
†Significant results are marked in bold.
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Our study showed that serum Nampt level may serve as 
a biomarker of BC and an independent prognostic mark-
er of non-muscle-invasive BC, with higher serum Nampt 
level indicating shorter recurrence-free survival rate. The 
use of biomarkers can provide detailed insight into can-
cer progression and metastasis, leading to more accurate 
and patient-specific prognosis and surveillance, and it can 
improve patients’ quality of life by enabling the use of less-
aggressive treatment options (18,19).
Human Nampt was originally characterized as a presump-
tive cytokine named pre-B-cell colony enhancing factor 
(PBEF) (20). Nampt was also claimed to function as an in-
sulin-mimetic adipocytokine named visfatin (21). Nampt 
exists in 2 known forms, iNampt and eNampt. iNampt is 
involved in angiogenesis by activating the extracellular sig-
nal regulated kinase (ERK)1/2 pathway and inducing vas-
cular endothelial growth factor and MMP2/9 production 
(22). Additionally, it induces the proliferation and capillary-
like tube formation in human umbilical vein endothelial 
cells in a dose- and time-dependent manner (23). These 
findings suggest that iNampt might have pro-angiogenic 
activity and support the growth of some types of tumors. 
Additionally, a chemical screen performed to identify com-
pounds that might affect mechanisms of cellular growth, 
survival, or death has yielded a potent small molecule in-
hibitor termed FK-866 (24). eNampt acts as a cytokine, in-
dependent of its enzymatic activity, and plays a major role 
in the regulation of immune responses (16).
Nampt is expressed throughout the body and secreted 
mainly by adipocytes and macrophages (25). Its activity 
has been shown to enhance cellular proliferation (26) and 
to tip the balance toward cell survival following a geno-
toxic insult (27). Also, Nampt plays a central role in control-
ling the circadian clock machinery by dictating the peri-
odical oscillations of some of its key transcription factors 
(28). At the immune level, it has been shown to promote 
myeloid (29) and lymphoid (30) differentiation and to in-
crease specific cytokine production (31). The complex reg-
ulatory network should in principle disqualify Nampt as a 
potential target for pharmacological intervention. Indeed, 
reduced NAD+ levels should affect the activity of several 
sirtuin members, causing multiple, and possibly unrelated, 
biological effects in vivo (32).
Other studies found that serum Nampt protein level was 
associated with tumor progression in patients with gastric 
cancer (33) and colorectal cancer (11). Nampt expression 
together with p53 expression was associated with shorter 
survival of glioblastoma patients (34). Nampt overexpres-
sion was also found to predict poor response to doxoru-
bicin-based chemotherapy in breast cancer treatment 
(35). Our study contributed to this body of evidence by 
showing that serum Nampt level may be an independent 
prognostic marker of non-muscle-invasive BC, with higher 
serum Nampt level indicating shorter recurrence-free sur-
vival rate.
Our previous study showed that rs61330082 in NAMPT pro-
moter region may predict BC risk and prognosis (17). How-
ever in this study there was no significant difference be-
tween the three genotypes in serum Nampt level, which 
implies that rs61330082 may not affect the bladder cancer 
risk and prognosis via influencing the serum Nampt level.
In conclusion, our study presents a novel finding that serum 
Nampt level may serve as biomarker of BC and an indepen-
dent prognostic marker of non-muscle-invasive BC. Nampt 
may be therefore a promising target for BC treatment, but 
its exact function in BC remains to be evaluated.
Funding This work was supported by the National Natural Science Foun-
dation of China (No. 81172440, No. 81172494, No. 81202023 and No. 
81272821); the Applied Basic Research Programs of Science and Technol-
ogy Commission Foundation of Sichuan Province (No. 2012SZ0008); and 
Program for Changjiang Scholars and Innovative Research Team in Univer-
sity (PCSIRT0935).
ethical approval received from the ethics committee of the West China 
Hospital of Sichuan University.
declaration of authorship KZ, BZ, and LZ contributed to research design; 
PZ, ZZ, and PC performed the sample collection; YP and YS performed the 
experiment; KZ and BZ performed data analysis; KZ wrote the manuscript; 
and LZ revised the manuscript.
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
reference
1  Ploeg M, aben KK, Kiemeney La. the present and future burden of 
urinary bladder cancer in the world. World J urol. 2009;27:289-93. 
Medline:19219610 doi:10.1007/s00345-009-0383-3
2 Botteman MF, Pashos CL, redaelli a, Laskin B, hauser r. the 
health economics of bladder cancer: a comprehensive review of 
the published literature. Pharmacoeconomics. 2003;21:1315-30. 
Medline:14750899 doi:10.1007/BF03262330
3 Jemal a, Siegel r, Xu J, Ward e. Cancer statistics, 2010. Ca Cancer J 
Clin. 2010;60:277-300. Medline:20610543 doi:10.3322/caac.20073
4 Cancer incidence in five continents. Volume iX. iarC Sci Publ. 
CLINICAL SCIENCE512 Croat Med J. 2014;55:507-13
www.cmj.hr
2008;(160):1-837. Medline:19388204
5 Soloway MS, Sofer M, Vaidya a. Contemporary management 
of stage t1 transitional cell carcinoma of the bladder. J urol. 
2002;167:1573-83. Medline:11912367 doi:10.1016/S0022-
5347(05)65157-9
6 Saad a, hanbury dC, Mcnicholas ta, Boustead GB, Morgan S, 
Woodman aC. a study comparing various noninvasive methods 
of detecting bladder cancer in urine. BJu int. 2002;89:369-73. 
Medline:11872026 doi:10.1046/j.1464-4096.2001.01699.x
7 Sylvester rJ. van der Ma, Lamm dL. intravesical bacillus 
Calmette-Guerin reduces the risk of progression in patients with 
superficial bladder cancer: a meta-analysis of the published 
results of randomized clinical trials. J urol. 2002;168:1964-70. 
Medline:12394686 doi:10.1016/S0022-5347(05)64273-5
8 revollo Jr, Grimm aa, imai S. the nad biosynthesis pathway 
mediated by nicotinamide phosphoribosyltransferase regulates 
Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754-63. 
Medline:15381699 doi:10.1074/jbc.M408388200
9 hufton Se, Moerkerk Pt, Brandwijk r, de Bruine aP, arends JW, 
hoogenboom hr. a profile of differentially expressed genes 
in primary colorectal cancer using suppression subtractive 
hybridization. FeBS Lett. 1999;463:77-82. Medline:10601642 
doi:10.1016/S0014-5793(99)01578-1
10 Van Beijnum Jr, Moerkerk Pt, Gerbers aJ, de Bruine aP, arends 
JW, hoogenboom hr, et al. target validation for genomics using 
peptide-specific phage antibodies: a study of five gene products 
overexpressed in colorectal cancer. int J Cancer. 2002;101:118-27. 
Medline:12209988 doi:10.1002/ijc.10584
11 nakajima te, Yamada Y, hamano t, Furuta K, Matsuda t, Fujita S, et 
al. adipocytokines as new promising markers of colorectal tumors: 
adiponectin for colorectal adenoma, and resistin and visfatin for 
colorectal cancer. Cancer Sci. 2010;101:1286-91. Medline:20331631 
doi:10.1111/j.1349-7006.2010.01518.x
12 Srivastava M, Khurana P, Sugadev r. Lung cancer signature 
biomarkers: tissue specific semantic similarity based clustering of 
digital differential display (ddd) data. BMC res notes. 2012;5:617. 
Medline:23122428 doi:10.1186/1756-0500-5-617
13 dalamaga M. nicotinamide phosphoribosyl-transferase/visfatin: 
a missing link between overweight/obesity and postmenopausal 
breast cancer? Potential preventive and therapeutic 
perspectives and challenges. Med hypotheses. 2012;79:617-21. 
Medline:22922056 doi:10.1016/j.mehy.2012.07.036
14 Wang B, hasan MK, alvarado e, Yuan h, Wu h, Chen WY. naMPt 
overexpression in prostate cancer and its contribution to tumor 
cell survival and stress response. oncogene. 2011;30:907-21. 
Medline:20956937 doi:10.1038/onc.2010.468
15 Bi tQ, Che XM, Liao Xh, Zhang dJ, Long hL, Li hJ, et al. 
overexpression of nampt in gastric cancer and chemopotentiating 
effects of the nampt inhibitor FK866 in combination with 
fluorouracil. oncol rep. 2011;26:1251-7. Medline:21743967
16 Garten a, Petzold S, Korner a, imai S, Kiess W. nampt: linking 
nad biology, metabolism and cancer. trends endocrinol Metab. 
2009;20:130-8. Medline:19109034 doi:10.1016/j.tem.2008.10.004
17 Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, et al. Genetic 
variants in naMPt predict bladder cancer risk and prognosis in 
individuals from southwest Chinese han group. tumour Biol. 
2014;35:4031-40. Medline:24363084 doi:10.1007/s13277-013-
1527-z
18 Feifer ah, taylor JM, tarin tV, herr hW. Maximizing cure for muscle-
invasive bladder cancer: integration of surgery and chemotherapy. 
eur urol. 2011;59:978-84. Medline:21257257 doi:10.1016/j.
eururo.2011.01.014
19 Stenzl a, Cowan nC, de Santis M, Kuczyk Ma, Merseburger 
aS, ribal MJ, et al. treatment of muscle-invasive and 
metastatic bladder cancer: update of the eau guidelines. 
eur urol. 2011;59:1009-18. Medline:21454009 doi:10.1016/j.
eururo.2011.03.023
20 Samal B, Sun Y, Stearns G, Xie C, Suggs S, Mcniece i. Cloning and 
characterization of the cdna encoding a novel human pre-
B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-7. 
Medline:8289818
21 Fukuhara a, Matsuda M, nishizawa M, Segawa K, tanaka M, 
Kishimoto K, et al. Visfatin: a protein secreted by visceral fat 
that mimics the effects of insulin. Science. 2005;307:426-30. 
Medline:15604363 doi:10.1126/science.1097243
22 Kim Sr, Bae SK, Choi KS, Park SY, Jun ho, Lee JY, et al. Visfatin 
promotes angiogenesis by activation of extracellular signal-
regulated kinase 1/2. Biochem Biophys res Commun. 
2007;357:150-6. Medline:17408594 doi:10.1016/j.bbrc.2007.03.105
23 adya r, tan BK, Punn a, Chen J, randeva hS. Visfatin induces 
human endothelial VeGF and MMP-2/9 production via MaPK and 
Pi3K/akt signalling pathways: novel insights into visfatin-induced 
angiogenesis. Cardiovasc res. 2008;78:356-65. Medline:18093986 
doi:10.1093/cvr/cvm111
24 hasmann M, Schemainda i. FK866, a highly 
specific noncompetitive inhibitor of nicotinamide 
phosphoribosyltransferase, represents a novel mechanism for 
induction of tumor cell apoptosis. Cancer res. 2003;63:7436-42. 
Medline:14612543
25 Friebe d, neef M, Kratzsch J, erbs S, dittrich K, Garten a, et 
al. Leucocytes are a major source of circulating nicotinamide 
phosphoribosyltransferase (naMPt)/pre-B cell colony (PBeF)/
visfatin linking obesity and inflammation in humans. diabetologia. 
2011;54:1200-11. Medline:21298414 doi:10.1007/s00125-010-
2042-z
26 Wang P, Xu tY, Guan YF, Su dF, Fan Gr, Miao CY. Perivascular 
adipose tissue-derived visfatin is a vascular smooth muscle cell 
growth factor: role of nicotinamide mononucleotide. Cardiovasc 
res. 2009;81:370-80. Medline:18952695 doi:10.1093/cvr/cvn288
27 Yang h, Yang t, Baur Ja, Perez e, Matsui t, Carmona JJ, et al. 
513Zhang et al: Nampt expression and bladder cancer
www.cmj.hr
nutrient-sensitive mitochondrial nad+ levels dictate cell survival. 
Cell. 2007;130:1095-107. Medline:17889652 doi:10.1016/j.
cell.2007.07.035
28 nakahata Y, Sahar S, astarita G, Kaluzova M, Sassone-Corsi P. 
Circadian control of the nad+ salvage pathway by CLoCK-
Sirt1. Science. 2009;324:654-7. Medline:19286518 doi:10.1126/
science.1170803
29 Skokowa J, Lan d, thakur BK, Wang F, Gupta K, Cario G, et al. 
naMPt is essential for the G-CSF-induced myeloid differentiation 
via a nad(+)-sirtuin-1-dependent pathway. nat Med. 
2009;15:151-8. Medline:19182797 doi:10.1038/nm.1913
30 rongvaux a, Galli M, denanglaire S, Van Gool F, dreze PL, Szpirer 
C, et al. nicotinamide phosphoribosyl transferase/pre-B cell 
colony-enhancing factor/visfatin is required for lymphocyte 
development and cellular resistance to genotoxic stress. J 
immunol. 2008;181:4685-95. Medline:18802071 doi:10.4049/
jimmunol.181.7.4685
31 Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov a, et 
al. intracellular nad levels regulate tumor necrosis factor protein 
synthesis in a sirtuin-dependent manner. nat Med. 2009;15:206-10. 
Medline:19151729 doi:10.1038/nm.1906
32 Gallí M, Van Gool F, rongvaux a, andris F, Leo o. the nicotinamide 
phosphoribosyltransferase: a molecular link between 
metabolism, inflammation, and cancer. Cancer res. 2010;70:8-11. 
Medline:20028851 doi:10.1158/0008-5472.Can-09-2465
33 nakajima te, Yamada Y, hamano t, Furuta K, Gotoda t, Katai h, et al. 
adipocytokine levels in gastric cancer patients: resistin and visfatin 
as biomarkers of gastric cancer. J Gastroenterol. 2009;44:685-90. 
Medline:19430715 doi:10.1007/s00535-009-0063-5
34 reddy PS, umesh S, thota B, tandon a, Pandey P, hegde aS, et al. 
PBeF1/namPrtase/Visfatin: a potential malignant astrocytoma/
glioblastoma serum marker with prognostic value. Cancer Biol 
ther. 2008;7:663-8. Medline:18728403 doi:10.4161/cbt.7.5.5663
35 Folgueira Ma, Carraro dM, Brentani h, Patrao dF, Barbosa eM, 
netto MM, et al. Gene expression profile associated with response 
to doxorubicin-based therapy in breast cancer. Clin Cancer res. 
2005;11:7434-43. Medline:16243817 doi:10.1158/1078-0432.CCr-
04-0548
